Biohaven Sets New Course with $258 Million in Cash, a Proven Team and Deep Pipeline to Continue its Journey to Advance Science for Patients
Broad therapeutic research and development portfolio includes more than 13 clinical and pre-clinical programs with a focus on neuroscience and rare disorders...
Source: prnewswire.com